5 completed. 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 5 |
Follow icotinib: new trials by email Literature Review of icotinib trials Research Report on icotinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma YiQiFang, YangYinFang, YiQiYangYinFang - Cancer | Phase 3 | Completed | Shanghai University of Traditional Chinese Medicine | 23 | 2013-03-01 | 2019-04-11 |
| Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients Icotinib, Chemotherapy - NSCLC | Phase 3 | Completed | Betta Pharmaceuticals Co., Ltd. | 296 | 2012-12-01 | 2019-07-05 |
| Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer whole brain radiation(WBI), Icotinib - Brain Metastasis, Non Small Cell Lung Cancer | Phase 3 | Completed | Guangdong Association of Clinical Trials | 176 | 2012-10-14 | 2017-03-01 |
| Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy icotinib - Non-small Cell Lung Cancer | Phase 3 | Completed | Betta Pharmaceuticals Co., Ltd. | 128 | 2010-03-01 | 2015-07-01 |
| Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients Icotinib, Gefitinib - Non-small Cell Lung Cancer | Phase 3 | Completed | Betta Pharmaceuticals Co., Ltd. | 399 | 2009-02-01 | 2014-02-14 |
Carcinoma, Non-Small-Cell Lung (3) · Brain Neoplasms (1) · Lung Neoplasms (1) · Neoplasms (1)
Betta Pharmaceuticals Co., Ltd. (3) · Guangdong Association of Clinical Trials (1) · Shanghai University of Traditional Chinese Medicine (1)
China (4)
Fenlai Tan, M.D./Ph.D. (1) · Jinji Yang, MD (1) · Li Zhang, M.D. (1) · Shi Yuankai, M.D. (1) · Yan Sun, M.D. (1) · Yan Sun, MD (1)
PMID 23948351, PMID 22112293, PMID 26599904, PMID 28734822, PMID 28945850